Oregon has become the first state in the United States to legalize psilocybin, the hallucinogenic component found in magic mushrooms, for mental health therapy in supervised settings.

---

A new small study of 24 people with major depression published this week in the journal JAMA Psychiatry found that two doses of psilocybin resulted in a significant reduction in depressive symptoms.

---

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” Alan Davis, an adjunct assistant professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, said in a news release.

---

“Because most other depression treatments take weeks or months to work and may have negative side effects, if these findings hold up in future ‘gold-standard’ placebo-controlled trials, this could be a game changer.”

Angermayer is now one of the driving forces behind the movement to turn long-shunned psychoactive substances, such as psilocybin derived from so-called magic mushrooms, into approved medications for depression and other mental illnesses, with a net worth of roughly $400 million amassed through various enterprises.

---

Though he still refuses to drink alcohol, he has assembled a group of like-minded businesspeople, including Silicon Valley billionaire Peter Thiel, to invest in a handful of firms focusing on the development of psychedelics.